{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T14:18:45Z","timestamp":1781014725948,"version":"3.54.1"},"reference-count":44,"publisher":"Elsevier BV","issue":"39","license":[{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,8,5]],"date-time":"2019-08-05T00:00:00Z","timestamp":1564963200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2019,9]]},"DOI":"10.1016\/j.vaccine.2019.08.001","type":"journal-article","created":{"date-parts":[[2019,8,20]],"date-time":"2019-08-20T08:26:57Z","timestamp":1566289617000},"page":"5877-5885","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"title":["The adjuvanted recombinant zoster vaccine co-administered with a tetanus, diphtheria and pertussis vaccine in adults aged \u226550 years: A randomized trial"],"prefix":"10.1016","volume":"37","author":[{"given":"Ana","family":"Strezova","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Himal","family":"Lal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2233-5242","authenticated-orcid":false,"given":"Igwebuike","family":"Enweonye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Campora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Beukelaers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathan","family":"Segall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4500-5676","authenticated-orcid":false,"given":"Thomas C.","family":"Heineman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3544-0682","authenticated-orcid":false,"given":"Anne E.","family":"Schuind","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lidia","family":"Oostvogels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Suppl 1","key":"10.1016\/j.vaccine.2019.08.001_b0005","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1086\/510206","article-title":"Recommendations for the management of herpes zoster","volume":"44","author":"Dworkin","year":"2007","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2019.08.001_b0010","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1056\/NEJMcp1302674","article-title":"Clinical practice: herpes zoster","volume":"369","author":"Cohen","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2019.08.001_b0015","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1586\/erv.10.30","article-title":"Herpes zoster and postherpetic neuralgia","volume":"9","author":"Johnson","year":"2010","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2019.08.001_b0020","doi-asserted-by":"crossref","first-page":"e004833","DOI":"10.1136\/bmjopen-2014-004833","article-title":"Systematic review of incidence and complications of herpes zoster: towards a global perspective","volume":"4","author":"Kawai","year":"2014","journal-title":"BMJ Open"},{"key":"10.1016\/j.vaccine.2019.08.001_b0025","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1212\/WNL.0b013e3182a3516e","article-title":"The global epidemiology of herpes zoster","volume":"81","author":"Yawn","year":"2013","journal-title":"Neurology"},{"key":"10.1016\/j.vaccine.2019.08.001_b0030","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1186\/s12879-015-1262-8","article-title":"Annual incidence rates of herpes zoster among an immunocompetent population in the United States","volume":"15","author":"Johnson","year":"2015","journal-title":"BMC Infect Dis"},{"issue":"Suppl 1","key":"10.1016\/j.vaccine.2019.08.001_b0035","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1016\/S1386-6532(10)70002-0","article-title":"Advances in the understanding of the pathogenesis and epidemiology of herpes zoster","volume":"48","author":"Gershon","year":"2010","journal-title":"J Clin Virol"},{"key":"10.1016\/j.vaccine.2019.08.001_b0040","first-page":"1","article-title":"Prevention of herpes zoster: recommendations of the Advisory Committee on Immunization Practices (ACIP)","volume":"57","author":"Harpaz","year":"2008","journal-title":"MMWR Recomm Rep"},{"key":"10.1016\/j.vaccine.2019.08.001_b0045","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1086\/605611","article-title":"Varicella-zoster virus-specific immune responses to herpes zoster in elderly participants in a trial of a clinically effective zoster vaccine","volume":"200","author":"Weinberg","year":"2009","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2019.08.001_b0050","first-page":"S13","article-title":"Herpes zoster pathogenesis and cell-mediated immunity and immunosenescence","volume":"109","author":"Oxman","year":"2009","journal-title":"J Am Osteopath Assoc"},{"key":"10.1016\/j.vaccine.2019.08.001_b0055","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1080\/14760584.2018.1495565","article-title":"Development of adjuvanted recombinant zoster vaccine and its implications for shingles prevention","volume":"17","author":"Lecrenier","year":"2018","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2019.08.001_b0060","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1056\/NEJMoa1501184","article-title":"Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults","volume":"372","author":"Lal","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2019.08.001_b0065","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1056\/NEJMoa1603800","article-title":"Efficacy of the herpes zoster subunit vaccine in adults 70 years of age or older","volume":"375","author":"Cunningham","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2019.08.001_b0070","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1093\/infdis\/jiy095","article-title":"Immune responses to a recombinant glycoprotein E herpes zoster vaccine in adults aged 50 years or older","volume":"217","author":"Cunningham","year":"2018","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2019.08.001_b0075","unstructured":"FDA. Shingrix prescribing information. Available at: <https:\/\/www.fda.gov\/downloads\/BiologicsBloodVaccines\/Vaccines\/ApprovedProducts\/UCM581605.pdf> [accessed 20 Mar 2019]."},{"key":"10.1016\/j.vaccine.2019.08.001_b0080","unstructured":"Health Canada. Summary basis of decision. Available at: <https:\/\/hpr-rps.hres.ca\/reg-content\/summary-basis-decision-detailTwo.php?linkID=SBD00377> [accessed 20 Mar 2019]."},{"key":"10.1016\/j.vaccine.2019.08.001_b0085","unstructured":"EMA. Shingrix. Summary of product characteristics. Available at: <http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/004336\/WC500246550.pdf> [accessed 20 Mar 2019]."},{"key":"10.1016\/j.vaccine.2019.08.001_b0090","doi-asserted-by":"crossref","first-page":"103","DOI":"10.15585\/mmwr.mm6703a5","article-title":"Recommendations of the advisory committee on immunization practices for use of herpes zoster vaccines","volume":"67","author":"Dooling","year":"2018","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.vaccine.2019.08.001_b0095","doi-asserted-by":"crossref","first-page":"i6258","DOI":"10.1136\/bmj.i6258","article-title":"Influenza","volume":"355","author":"Ghebrehewet","year":"2016","journal-title":"BMJ"},{"key":"10.1016\/j.vaccine.2019.08.001_b0100","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1016\/j.vaccine.2006.09.041","article-title":"Influenza- and RSV-associated hospitalizations among adults","volume":"25","author":"Mullooly","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.08.001_b0105","doi-asserted-by":"crossref","first-page":"763","DOI":"10.2217\/ahe.09.74","article-title":"Community-acquired pneumonia in elderly patients","volume":"5","author":"Stupka","year":"2009","journal-title":"Aging Health"},{"key":"10.1016\/j.vaccine.2019.08.001_b0110","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1186\/s12879-015-1269-1","article-title":"The estimated incidence of pertussis in people aged 50 years old in the United States, 2006\u20132010","volume":"15","author":"Masseria","year":"2015","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.vaccine.2019.08.001_b0115","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/1471-2334-13-32","article-title":"The disease burden of pertussis in adults 50 years old and older in the United States: a retrospective study","volume":"13","author":"McGuiness","year":"2013","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.vaccine.2019.08.001_b0120","doi-asserted-by":"crossref","first-page":"660","DOI":"10.7326\/0003-4819-136-9-200205070-00008","article-title":"Serologic immunity to diphtheria and tetanus in the United States","volume":"136","author":"McQuillan","year":"2002","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.vaccine.2019.08.001_b0125","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1097\/01.inf.0000202082.56403.c4","article-title":"How soon after a prior tetanus-diphtheria vaccination can one give adult formulation tetanus-diphtheria-acellular pertussis vaccine?","volume":"25","author":"Halperin","year":"2006","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2019.08.001_b0130","doi-asserted-by":"crossref","first-page":"22","DOI":"10.7774\/cevr.2017.6.1.22","article-title":"Tetanus-diphtheria-acellular pertussis vaccination for adults: an update","volume":"6","author":"Lee","year":"2017","journal-title":"Clin Exp Vaccine Res"},{"key":"10.1016\/j.vaccine.2019.08.001_b0135","unstructured":"CDC. Epidemiology and prevention of vaccine-preventable diseases: pertussis. Available at: <https:\/\/www.cdc.gov\/vaccines\/pubs\/pinkbook\/pert.html> [accessed 20 Mar 2019]."},{"key":"10.1016\/j.vaccine.2019.08.001_b0140","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15585\/mmwr.rr6702a1","article-title":"Prevention of pertussis, tetanus, and diphtheria with vaccines in the United States: recommendations of the advisory committee on immunization practices (ACIP)","volume":"67","author":"Liang","year":"2018","journal-title":"MMWR Recomm Rep"},{"key":"10.1016\/j.vaccine.2019.08.001_b0145","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1093\/infdis\/jix481","article-title":"Immunogenicity and safety of an adjuvanted herpes zoster subunit vaccine coadministered with seasonal influenza vaccine in adults aged 50 years or older","volume":"216","author":"Schwarz","year":"2017","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2019.08.001_b0150","doi-asserted-by":"crossref","first-page":"4278","DOI":"10.1016\/j.vaccine.2018.05.110","article-title":"Immunogenicity and safety of the adjuvanted recombinant zoster vaccine co-administered with the 23-valent pneumococcal polysaccharide vaccine in adults \u226550 years of age: a randomized trial","volume":"36","author":"Marechal","year":"2018","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.08.001_b0155","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1093\/biomet\/26.4.404","article-title":"The use of confidence or fiducial limits illustrated in the case of the binomial","volume":"26","author":"Clopper","year":"1934","journal-title":"Biometrika"},{"key":"10.1016\/j.vaccine.2019.08.001_b0160","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1002\/(SICI)1097-0258(19980430)17:8<873::AID-SIM779>3.0.CO;2-I","article-title":"Interval estimation for the difference between independent proportions: comparison of eleven methods","volume":"17","author":"Newcombe","year":"1998","journal-title":"Stat Med"},{"key":"10.1016\/j.vaccine.2019.08.001_b0165","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1093\/infdis\/jit365","article-title":"Safety and immunogenicity of an AS01-adjuvanted varicella-zoster virus subunit candidate vaccine against herpes zoster in adults \u226550 years of age","volume":"208","author":"Chlibek","year":"2013","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2019.08.001_b0170","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1016\/j.vaccine.2014.01.019","article-title":"Safety and immunogenicity of three different formulations of an adjuvanted varicella-zoster virus subunit candidate vaccine in older adults: a phase II, randomized, controlled study","volume":"32","author":"Chlibek","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.08.001_b0175","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1093\/ofid\/ofw194.40","article-title":"Efficacy, immunogenicity and safety of an investigational subunit adjuvanted herpes zoster vaccine in adults aged 60 years and older: results from the ZOE-50 and ZOE-70 efficacy studies","volume":"3","author":"McElhaney","year":"2016","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.vaccine.2019.08.001_b0180","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1128\/jcm.20.4.772-774.1984","article-title":"Immunoenzymatic assay of anti-diphtheric toxin antibodies in human serum","volume":"20","author":"Camargo","year":"1984","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.vaccine.2019.08.001_b0185","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/S0092-1157(83)80038-9","article-title":"A comparison of enzyme-linked immunosorbent assay (ELISA) with the toxin neutralization test in mice as a method for the estimation of tetanus antitoxin in human sera","volume":"11","author":"Melville-Smith","year":"1983","journal-title":"J Biol Stand"},{"key":"10.1016\/j.vaccine.2019.08.001_b0190","unstructured":"WHO. Acellular pertussis vaccines. Available at: <http:\/\/www.who.int\/biologicals\/areas\/vaccines\/apertussis\/en\/> [accessed 20 Mar 2019]."},{"key":"10.1016\/j.vaccine.2019.08.001_b0195","doi-asserted-by":"crossref","first-page":"858","DOI":"10.4161\/hv.9961","article-title":"Safety and immunogenicity of a tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine when co-administered with influenza vaccine in adults","volume":"5","author":"Weston","year":"2009","journal-title":"Hum Vaccin"},{"key":"10.1016\/j.vaccine.2019.08.001_b0200","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1016\/j.vaccine.2014.09.064","article-title":"Immunogenicity and reactogenicity of InfanrixTM when co-administered with meningococcal MenACWY-TT conjugate vaccine in toddlers primed with MenHibrixTM and PediarixTM","volume":"33","author":"Leonardi","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.08.001_b0205","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/S0022-3476(96)70152-X","article-title":"Clinical experience of a tricomponent acellular pertussis vaccine combined with diphtheria and tetanus toxoids for primary vaccination in 22,505 infants","volume":"129","author":"Schmitt","year":"1996","journal-title":"J Pediatr"},{"key":"10.1016\/j.vaccine.2019.08.001_b0210","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1001\/jama.1996.03530250041024","article-title":"Efficacy of acellular pertussis vaccine in early childhood after household exposure","volume":"275","author":"Schmitt","year":"1996","journal-title":"JAMA"},{"key":"10.1016\/j.vaccine.2019.08.001_b0215","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1016\/j.vaccine.2010.11.057","article-title":"Immunogenicity and reactogenicity of co-administered tetanus-diphtheria-acellular pertussis (Tdap) and tetravalent meningococcal conjugate (MCV4) vaccines compared to their separate administration","volume":"29","author":"Weston","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.08.001_b0220","unstructured":"GSK. Clinical study register (study ID 208355\/022) Available at: <https:\/\/www.gsk-studyregister.com\/study\/6176> [accessed 20 Mar 2019]."}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X19310266?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X19310266?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T10:35:20Z","timestamp":1759401320000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X19310266"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9]]},"references-count":44,"journal-issue":{"issue":"39","published-print":{"date-parts":[[2019,9]]}},"alternative-id":["S0264410X19310266"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2019.08.001","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2019,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The adjuvanted recombinant zoster vaccine co-administered with a tetanus, diphtheria and pertussis vaccine in adults aged \u226550 years: A randomized trial","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2019.08.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 GSK. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}